{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=growth+factor+antagonist+therapy", "query": { "intervention": "growth factor antagonist therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=growth+factor+antagonist+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T01:59:09.368Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07063212", "title": "A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Sinus Cancer", "Nasal Cavity Cancer", "Oral Cavity Cancer", "Oropharynx Cancer", "Hypopharynx Cancer", "Larynx Cancer", "Oral Squamous Cell Carcinoma", "Oropharynx Squamous Cell Carcinoma", "Hypopharynx Squamous Cell Carcinoma", "Larynx Squamous Cell Carcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Sacituzumab Govitecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-07-02", "completion_date": "2028-01-02", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07063212" }, { "nct_id": "NCT05271604", "title": "A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Carcinoma of Head and Neck", "Recurrent Squamous Cell Carcinoma of the Head and Neck", "Metastatic Cancer", "Metastatic Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Ozuriftamab Vedotin", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Evalstotug (BA3071)", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2022-12-13", "completion_date": "2025-09-22", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 7, "location_summary": "Los Angeles, California • Newark, Delaware • Chicago, Illinois + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05271604" }, { "nct_id": "NCT00994123", "title": "A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2010-02", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-08-22", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00994123" }, { "nct_id": "NCT03387111", "title": "QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Necitumumab", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-01-09", "completion_date": "2021-01-11", "has_results": true, "last_update_posted_date": "2024-08-05", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03387111" }, { "nct_id": "NCT00819780", "title": "PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Colorectal Cancer", "Rectal Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Panitumumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2009-04-24", "completion_date": "2016-07-07", "has_results": true, "last_update_posted_date": "2022-12-06", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Berkeley, California + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00819780" }, { "nct_id": "NCT00009841", "title": "Gene Therapy in Treating Patients With Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "EGFR antisense DNA", "type": "BIOLOGICAL" }, { "name": "growth factor antagonist therapy", "type": "BIOLOGICAL" }, { "name": "DC-cholesterol liposome", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 13, "start_date": "1999-03", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2016-02-12", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00009841" }, { "nct_id": "NCT00450463", "title": "Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Sargramostim (GM-CSF, Leukine)", "type": "DRUG" }, { "name": "Flutamide (Eulexin)", "type": "DRUG" }, { "name": "PROSTVAC-F/ TRICOM", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-V/TRICOM", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "MALE", "summary": "18 Years to 110 Years · Male only" }, "enrollment_count": 64, "start_date": "2007-02-23", "completion_date": "2017-06-08", "has_results": true, "last_update_posted_date": "2018-11-29", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 3, "location_summary": "Bethesda, Maryland • New Brunswick, New Jersey • Philadelphia, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450463" }, { "nct_id": "NCT07811232", "title": "A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrial Neoplasms", "Soft Tissue Sarcoma (STS)", "Breast Neoplasms" ], "interventions": [ { "name": "AL58805", "type": "DRUG" }, { "name": "AL8326", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advenchen Pharmaceuticals, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2026-09-01", "completion_date": "2031-09-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07811232" }, { "nct_id": "NCT07188090", "title": "Mozobil for Autologous Hematopoietic Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" }, { "name": "Gcsf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-10-16", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07188090" }, { "nct_id": "NCT07037420", "title": "ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acromegaly" ], "interventions": [ { "name": "ALXN2420", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 8, "start_date": "2025-10-28", "completion_date": "2026-06-24", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-28T01:59:09.368Z", "location_count": 2, "location_summary": "Torrance, California • Ann Arbor, Michigan", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07037420" } ] }